Sodium nitroprusside intravenous - Exela Pharma Sciences

Drug Profile

Sodium nitroprusside intravenous - Exela Pharma Sciences

Alternative Names: NIPRIDE RTU; Sodium nitroprusside - RTU

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exela Pharma Sciences
  • Class Antihypertensives; Heart failure therapies; Peripheral vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Acute heart failure

Most Recent Events

  • 31 Mar 2017 Chemical structure information added
  • 09 Mar 2017 Registered in Acute heart failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top